Yoshikazu Kinoshita1, Tsutomu Chiba. 1. Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, Japan. kinosita@med.shimane-u.ac.jp
Abstract
BACKGROUND: A therapeutic strategy for symptomatic patients with chronic gastritis has not been established. Gastric acid has been reported to induce a variety of unpleasant abdominal symptoms. We investigated whether the histamine H2 receptor antagonist famotidine attenuated upper abdominal symptoms in patients with chronic gastritis. METHODS: In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks. The intensity levels of upper abdominal symptoms, epigastralgia, epigastric fullness, and heartburn were evaluated using a face scale (grade 0-4). Abdominal symptom-related quality of life (QOL) impairment was also evaluated, using an Izumo scale before and after famotidine administration. In a subgroup analysis, symptomatic responses in patients diagnosed with functional dyspepsia (FD) according to the Rome III criteria were analyzed. RESULTS: In 8,460 patients who completed the protocol, famotidine administration significantly attenuated epigastralgia, epigastric fullness, and heartburn, and famotidine also attenuated abdominal symptom-related QOL impairment in all patients with chronic symptomatic gastritis, in those with FD-like symptoms without organic disease, and in those with FD as defined by the Rome III criteria. CONCLUSION: Famotidine is effective to relieve abdominal symptoms and improve QOL, not only in patients with Rome III-defined FD, but also in those with chronic symptomatic gastritis.
BACKGROUND: A therapeutic strategy for symptomatic patients with chronic gastritis has not been established. Gastric acid has been reported to induce a variety of unpleasant abdominal symptoms. We investigated whether the histamine H2 receptor antagonist famotidine attenuated upper abdominal symptoms in patients with chronic gastritis. METHODS: In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks. The intensity levels of upper abdominal symptoms, epigastralgia, epigastric fullness, and heartburn were evaluated using a face scale (grade 0-4). Abdominal symptom-related quality of life (QOL) impairment was also evaluated, using an Izumo scale before and after famotidine administration. In a subgroup analysis, symptomatic responses in patients diagnosed with functional dyspepsia (FD) according to the Rome III criteria were analyzed. RESULTS: In 8,460 patients who completed the protocol, famotidine administration significantly attenuated epigastralgia, epigastric fullness, and heartburn, and famotidine also attenuated abdominal symptom-related QOL impairment in all patients with chronic symptomatic gastritis, in those with FD-like symptoms without organic disease, and in those with FD as defined by the Rome III criteria. CONCLUSION:Famotidine is effective to relieve abdominal symptoms and improve QOL, not only in patients with Rome III-defined FD, but also in those with chronic symptomatic gastritis.
Authors: H Miwa; S Hirai; A Nagahara; T Murai; T Nishira; S Kikuchi; Y Takei; S Watanabe; N Sato Journal: Aliment Pharmacol Ther Date: 2000-03 Impact factor: 8.171
Authors: M Kato; M Watanabe; S Konishi; M Kudo; J Konno; T Meguro; S Kitamori; S Nakagawa; Y Shimizu; H Takeda; M Asaka Journal: Aliment Pharmacol Ther Date: 2005-06 Impact factor: 8.171
Authors: Sander J O Veldhuyzen van Zanten; Naoki Chiba; David Armstrong; Alan Barkun; Alan Thomson; Sandra Smyth; Sergio Escobedo; Joanna Lee; Paul Sinclair Journal: Am J Gastroenterol Date: 2005-07 Impact factor: 10.864
Authors: T Kamada; K Haruma; J Hata; H Kusunoki; A Sasaki; M Ito; S Tanaka; M Yoshihara Journal: Aliment Pharmacol Ther Date: 2003-07-15 Impact factor: 8.171
Authors: David A Peura; Thomas O G Kovacs; David C Metz; Nancy Siepman; Betsy L Pilmer; Nicholas J Talley Journal: Am J Med Date: 2004-06-01 Impact factor: 4.965